Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | PHASE1 | RECRUITING | 30 | — | — | Aug 11, 2023 | Dec 31, 2027 | Sep 21, 2023 | 2 | China |
The incidence of adverse events (TEAE) after treatment; Incidence of treatment-related adverse events; Adverse evens of Special Interest (AESI);
Incidence and number of dose-limiting toxicity (DLT) cases，Dose-limiting toxicity after CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 2-10x10\^6 cells/kg |
| Name | Type | Description |
|---|---|---|
| CEA-targeted CAR-T cells | BIOLOGICAL | Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion. |
Inclusion Criteria: 1. Age ≥18 years old, male or female; 2. Patients with advanced malignant solid tumors confirmed by histology or pathology, including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, and cholangiocarcinoma; 3. Pr...